X.T.L. Biopharmaceuticals Ltd. - ADR

X.T.L. Biopharmaceuticals Ltd. - ADR

XTLB

Get informed when a big investor buys or sells

+ Follow
Market Cap$6.01M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
X.T.L. Biopharmaceuticals Ltd. - ADRX.T.L. Biopharmaceuticals Ltd. - ADR-4--19%0.7-
$6.82

Current Fair Value

144.6% upside

Undervalued by 144.6% based on the discounted cash flow analysis.

Share Statistics

Market cap$6.01 Million
Enterprise Value$5.79 Million
Dividend Yield$- (-)
Earnings per Share$-9.6
Beta0.56
Outstanding Shares105,163

Return

Return on Equity-18.90%ROE
Return on Assets-12.01%
Return on Invested Capital-31.75%

Valuation & Multiples

P/E Ratio-3.99P/E Ratio
PEG39.09PEG
Price to Sales0.7Price to Sales
Price to Book Ratio0.05Price to Book Ratio
Enterprise Value to Revenue12.85
Enterprise Value to EBIT-2.88
Enterprise Value to Net Income-6
Total Debt to Enterprise0.03
Debt to Equity0.03Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
April 29, 2026
EPS Estimate
-
Average shareholder expectation
Revenue Estimate
-
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %69.13% 9.25%
Total Invested$175,378 8.12%
Investors Holding60%

ESG Score

No data

About X.T.L. Biopharmaceuticals Ltd.

2,020 employees
CEO: Joshua Levine